Daratumumab-Based Regimens Are Highly Effective and Well Tolerated in Relapsed or Refractory Multiple Myeloma Regardless of Patient Age: Subgroup Analysis of the Phase 3 CASTOR and POLLUX Studies

Haematologica - Italy
doi 10.3324/haematol.2019.217448
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Once- Versus Twice-Weekly Carfilzomib in Relapsed and Refractory Multiple Myeloma by Select Patient Characteristics: Phase 3 A.R.R.O.W. Study Subgroup Analysis

Blood Cancer Journal
OncologyHematology
2020English

Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Daratumumab vs. Pomalidomide for the Treatment of Relapsed/Refractory Multiple Myeloma: A Cost‐effectiveness Analysis

American Journal of Hematology
Hematology
2018English

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2018English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma

Cancer
Cancer ResearchOncology
2018English

Lenalidomide Plus Dexamethasone Is More Effective Than Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Regardless of Prior Thalidomide Exposure

Blood
BiochemistryImmunologyCell BiologyHematology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy